Early data show Bicara’s bispecific helps shrink head and neck cancers when combined with Keytruda: #ASCO23
Bicara’s bispecific antibody treatment on top of Keytruda led to tumor shrinkage in about half of patients with head and neck cancer that has relapsed, according to early results shared at ASCO on Monday. While still in a small group of patients, response rates in patients with HPV-negative disease — which typically has worse outcomes — were especially notable.
In 31 patients with recurrent or metastatic head and neck squamous cell carcinoma, 15 responded to the combo treatment with Bicara’s antibody, known as BCA101, and Keytruda, Merck’s checkpoint inhibitor. One patient saw signs of cancer disappear completely, while the other 14 had partial responses. In addition, eight patients had stable disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.